This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The UK’s unique offering as a lifesciences research hub helped convince US biotech Novavax to develop its COVID-19 jab there, according to the head of the country’s Vaccines Taskforce. . It is really important and we have seen a lot of pharmacompanies interested in the UK.
If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the lifesciences. Here is a look at some lifescience trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.
Before the Covid-19 pandemic, government-led investment and engagement in lifesciences was relatively restricted worldwide, with the industry mostly funded via private investment. This included more than £6bn ($7.3bn) being made available by the UK Government in November 2020 for the development and procurement of successful vaccines.
ODAIA, a lifesciences predictive analytics and commercial insights provider, has secured an investment of $25m in its Series B funding round. This software-as-a-service (SaaS) platform is also used by lifescience brands to launch their drugs, therapeutics and vaccines in the markets, using data-driven solution.
In 2023, there were significant advancements and notable trends in the lifesciences. Xtalks compiled a list of its top lifescience news and trends of 2023, which provided readers with the latest developments, information and expert insights across lifescience industries, including pharma, biotech and medical device.
UK chancellor Rishi Sunak has been urged to recognise the leading role that pharmacompanies are playing in the economy in this week’s budget. According to a report last month from the BioIndustry Association, covering lifesciences and biotech, there was a record $2.8
The lifesciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the lifesciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.
Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Vaccine access for a price. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general.
Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals. What are the major challenges you’re facing right now in vaccine development?
The editorial team discussed the high costs associated with orphan drugs and how both governments and pharmacompanies must work together to make them accessible to patients. The team also talked about a digital risk report that revealed the existence of significant cybersecurity vulnerabilities among the world’s top pharmacompanies.
For the past year, lifesciencecompanies around the world worked at breakneck speed to develop and manufacture safe and effective treatments to respond to the COVID-19 pandemic. It is not only COVID-19 vaccines and therapeutics that benefit from a more regionalised approach. About the author. Dr Subir K.
The top ten pharmacompanies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 The top big pharma players have remained relatively consistent in their market positions over the past several years. Here is a look at the top ten pharmacompanies in 2024 based on 2023 revenue.
The past two years have shone a spotlight on the UK lifesciences industry. Pharmacompanies are now household names, having been thrust into the public’s consciousness after dominating the headlines through the pandemic. An industry that will forever play a greater role in our everyday lives. About the author.
UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery and as head of the UK vaccines taskforce. But Dix has also been leading the UK’s Vaccine Taskforce, after taking over the hot seat in December following the departure of Kate Bingham.
We’ve got so many great lifescience assets in the UK, but there are still some gaps – manufacturing capacity being one of them.”. “We We had companies collaborating to develop laboratories. We had companies sourcing consumables for testing machines. The road to a vaccine. A collaborative future.
The latest pharmacompany to make a move for an mRNA specialist is Germany’s Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. Outsourcing services are on of the pillars of Merck’s business, delivered via its process solutions unit, part of the group’s lifesciences division.
Regeneron and Eli Lilly have already got antibody therapies on the market following emergency approvals by regulators including the FDA but pharmacompanies are beginning to focus on the threat posed by emerging variants.
For pharmacompanies, COVID-19 has proved that they can be agile and responsive to rapidly evolving market conditions, as evidenced by the way they have adjusted to a new global paradigm while successfully continuing operations. Preparing for an agile pharma future. Jeremy Richter, Tag. Build on the rapid responses to COVID-19.
Today the whole world is in a search for an effective vaccine candidate against SARS-CoV-2. The vaccine appears to be the only solution to prevent coronavirus. Several pharma and biotech companies are developing and manufacturing safe and effective vaccines to fight coronavirus.
People who trust pharma are more interested in using the industry’s services – making building confidence in the sector key to realising the potential of patient centricity. However, according to Jennifer Turcotte, pharma advisor in the company’s healthcare and lifesciences division, there was also some good news.
Findings from an analysis conducted by Constella Intelligence , a digital risk protection company, show widespread cybersecurity vulnerabilities that are costing pharmacompanies significantly. The report includes information on breaches, exposures and leaks in the pharma sphere. Pharma Cybersecurity and Cyber Attacks.
In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the lifescience industry together through first holding physical events, then soon after, hosting exclusively online events. Pfizer is also the co-developer of what is arguably the most successful COVID-19 vaccine rollout.
With vaccine trials for COVID-19 ramping up and entering late stages, Johnson & Johnson has announced plans for what will be the largest Phase III trial so far for a vaccine against the novel coronavirus. This is double the enrollment that vaccine makers Moderna and Pfizer have planned for their Phase III trials.
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharmacompanies in the world: AstraZeneca.
Pharmacompanies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research. There’s also that risk of a perceived coercion or influence. There’s sometimes a bit of a barrier,” he added.
Eradicating cancer is an ambitious goal for oncologists and lifesciencecompanies around the world. As this issue’s contributors discuss, by working together pharmacompanies and healthcare providers can significantly enhance oncology treatment for patients. Realising the promise of cancer vaccines.
A director in lifesciences consulting for EY, she works within the commercial space for such companies, as well as their clients. “My We looked at the areas of rare diseases, cell and gene therapy, vaccines – loads of different perspectives. Innovative offerings around market access. Smart reviewing: utilising AI and ML.
These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. In 2023, Moderna is poised to achieve sales figures ranging from $6 billion to $8 billion, contingent on the prevailing COVID-19 vaccination rates in the US. vaccine, mRNA-1273.815.
That culture clash makes it hard to innovate the world of pharma at scale and with any rapidity. And investment in pharma followed suit: pharmacompanies were looked at as stable assets — reliable but unlikely to balloon in value like a tech company might. Start-ups move fast and break things.
The companys COVID-19 vaccine Comirnaty recorded revenues of $3.4 Pfizers COVID-19 oral treatment Paxlovid (nirmatrelvir/ritonavir) generated revenues of $727 million in the fourth quarter of 2024, reflecting a significant operational increase compared to the prior-year quarter.
The cell line, called HeLa, laid the foundation for many groundbreaking discoveries, including vaccines for the human papilloma virus (HPV) and polio; drugs for HIV and cancers; gene mapping; IVF treatment; and more recently, for crucial COVID-19 research. Fittingly, it was also used to develop the vaccine against cervical cancer.
The sharing of knowledge has already been critical in the industry’s collaborative efforts to expedite a COVID-19 vaccine, and Nikitczuk believes that this open approach should extend beyond research into the software and data tools pharma uses every day. About the interviewees.
With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies. He notes that it already has 21 partnerships with pharmacompanies and will aim to keep more product rights than it did in the past. Role models.
When it comes to pharma marketing, historically companies have had to either market direct to consumers — and trust them to find a doctor and bring up the company’s product with them — or to send sales reps to doctors — and hope they had the right mix of potential customers among their patients.
COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right circumstances – but there is much to do to ensure this progress is not lost, said speakers at WIRED Health 2021, including the CEOs of BioNTech and BenevolentAI. . BioNTech seeks “new kind of pharmacompany”.
Like most pharmacompanies of its size, Pfizer has faced its fair share of controversy as one of the most well-known drugmakers in the world. Despite some setbacks, Pfizer remains one of the biggest pharmacompanies in the world today. No signs of slowing down.
While infectious disease experts and drug companies have rightfully spent the last 18 months developing therapeutics and vaccines targeting SARS-CoV-2 and COVID-19, another global threat to public health — antimicrobial resistance (AMR) — has, and will continue to, persist until similar direct action is taken. That is, until now.
However, during the last months, due to COVID-19, we have observed how pharmaceutical companies have progressed very quickly through all the clinical development phases and different companies have already reached the clinical Phase III.
Pharma has a great opportunity ahead of it when it comes to conducting representative clinical trials. The industry’s application of mRNA techniques during the pandemic led to the fastest vaccine development in history. Whilst this is an early area of research, pharma can turn the dial now. About the author.
As Pfizer and BioNTech announced news of a possible Covid-19 vaccine on November 8 , in haste, pharma leaders are rallying to ensure supply chains will be able to support distribution. Read on to find out how the pharma industry are preparing for the future. Save your early bird seat now. Download a copy of the report here.
Takeda Pharmaceutical (Rank 86) Takeda Pharmaceutical, based in Japan, is dedicated to discovering and providing life-changing treatments across key therapeutic and business domains, encompassing gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.
In November 2020 during the third quarter, Berkshire spent billions of dollars on shares of four US pharma giants: AbbVie, Bristol Myers Squibb, Merck & Co. This was likely fueled by the flurry of development happening in the pharma space with COVID-19 vaccines and therapeutics. and Pfizer.
In my current role, I have country-level responsibility for AstraZeneca’s entire portfolio, including cardiovascular, respiratory, vaccines and oncology. Considering how challenging market access can be for large, established pharmacompanies, what does it look like on the small biotech level?
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content